Compound Radar

Glaukos Corporation (GKOS) Stock Analysis

United States · Healthcare / Medical Devices

Price $185.04
Market cap $10.91B
Next earnings Oct 28, 2026
Entry status Wait $130.88–$136.90

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 40
  • Profitability 45
  • Business Quality 65
  • Balance Sheet 45
  • Cash Flow 25

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 65/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Glaukos Corporation (GKOS) is a Medical Devices company in the Healthcare sector. Compound Radar rates Glaukos Corporation 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched
  • Valuation Elevated

Financial highlights

Valuation

  • Forward P/E 366.9
  • EV/Revenue 16.78

Profitability

  • Revenue Growth 49.5%
  • Gross Margin 79.1%
  • Operating Margin -8.5%
  • Net Margin -30.7%
  • ROE -26.0%

Financial strength

  • Cash $286.23M
  • Debt $107.60M
  • Net Cash $178.62M
  • Free Cash Flow $-39.06M
  • Current Ratio 5.04

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Glaukos Corporation (GKOS).

View Methodology & FAQ →